An injectable composite material containing bone morphogenetic protein-2 shortens the period of distraction osteogenesis in vivo.
To investigate new methods that can decrease the duration of bone transport (BT) distraction osteogenesis, we injected composite materials containing recombinant human bone morphogenetic protein-2 (BMP-2) and induced the generation of a callus bridge by rapid segmental transport (4 mm/day) in a rabbit bone defect model. The composite materials consisted of BMP-2 (0, 30, or 100 µg), β-tricalcium phosphate powder (βTCP, 100 mg/animal; particle size, <100 µm), and polyethylene glycol (PEG; 40 mg/animal). A paste of equivalent composition was percutaneously injected at the lengthening and the docking sites after surgery and after BT, respectively. The radiographic, mechanical, and histological examinations 12 weeks post-operative revealed that the generation of bridging callus in the presence and in the absence of BMP-2 was significantly different. The callus mass in the bone defect region was adequately and consistently developed in the presence of 100 µg of BMP (administered for 6 weeks), and the bones were consolidated in 12 weeks. Such an adequate callus formation was not observed in the control animals without BMP-2 treatment. The result of this experimental study suggests the potential application of BMP-2 in accelerating callus formation and in enabling rapid bone transporting, thereby shortening the treatment period for the repair of diaphyseal bone defects by distraction osteogenesis.
Eguchi
Yoshitaka
Y
Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. y-eguchi@med.osaka-cu.ac.jp
Wakitani
Shigeyuki
S
Naka
Yoshifumi
Y
Nakamura
Hiroaki
H
Takaoka
Kunio
K
D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology*; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D002146:Bony Callus / Q000187:drug effects* / Q000502:physiology; D002130:Calcium Phosphates / Q000494:pharmacology*; D018483:Diaphyses / Q000000981:diagnostic imaging / Q000293:injuries / Q000503:physiopathology; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000379:methods; D008297:Male; D019857:Osteogenesis, Distraction / Q000379:methods*; D011817:Rabbits; D011859:Radiography; D011994:Recombinant Proteins / Q000494:pharmacology; D013978:Tibial Fractures / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D002130:Calcium Phosphates; D011994:Recombinant Proteins; C485817:beta-tricalcium phosphate